Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Cell-free nucleic acids in cancer patients' blood
3. Serum/plasma DNA vs. tumor tissue DNA
4. Circulating DNA & nucleosides in breast tumors
5. LOCH frequency on cell-free DNA in the serum
6. Monitoring of the efficacy of systemic therapies
7. Circulating DNA in ovarian cancer patients
8. Circulating microns (mires) as biomarkers
9. Circulating mires in breast cancer
10. Circulating mires in ovarian cancer
11. Circulating mires in lung cancer (NASAL)
12. Cell-free DNA as an indicator of disease
13. Tumor cell circulation and cancer dormancy
14. CATCH & the microenvironment of metastasis sites
15. CATCH enrichment methods
16. CTC/DTC identification methods
17. Detection of circulating tumor cells by EPISPOT
18. Circulating free DNA & CATCH in prostate cancer (1)
19. Circulating free DNA & CATCH in prostate cancer (2)
20. Detection of DTC in bone marrow
21. Circulating free DNA as potential DTC biomarker
22. Molecular characterization of single CATCH
23. Genetic analysis of single CATCH in CRC patients
24. KRAS mutation analysis on plasma DNA
25. Genomic profiling of a single CATCH by CGH
26. Conclusions
27. Circulating nucleic acids in cancer patients
28. Cell-free DNA induces oncogenic transformation
29. Cell-free DNA as bio-markers - review

Topics Covered

• Circulating Nucleic Acids
• Advantages of Serum/Plasma DNA vs. Tumor Tissue DNA
• Circulating DNA in patients with benign disease and malignant tumors
• Circulating microRNAs in cancer patients
• Associations between Circulating Tumor Cells and cell-free tumor DNA in cancer patients

Links

Series:

• Biomarkers

Categories:

• Cancer
• Cell Biology
• Clinical Practice

Therapeutic Areas:

• Oncology

Talk Citation

Pantel, K. (2012, September 27). Circulating nucleic acids as biomarkers in cancer patients [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/CPUY7210.
Export Citation (RIS)

Publication History

• Published on September 27, 2012

Financial Disclosures

• Prof. Klaus Pantel has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.